Gastrointestinal effects: the main titration bottleneck Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose. In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg. They concentrate during escalation and ease with time on a held dose
All dosing figures describe a documented research protocol, not clinical guidance
A review published in Cureus (2024) noted that while TB-500 shows promise for soft tissue regeneration, additional research is necessary before clinical translation can occur
Our friendly team is ready to help with no long waits and no complicated referrals
Select your plan & get started today
Sharper focus : B12 supports healthy nerve function and mental clarity